AstraZeneca’s Imfinzi meets endpoint at Phase 3 interim analysis in extensive-stage small cell lung cancer
pharmafile | June 27, 2019 | News story | Research and Development | AstraZeneca, Imfinzi, pharma
AstraZeneca has lifted the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage small cell lung cancer (SCLC), illustrating that the therapy met its primary endpoint in a planned interim analysis carried out by an independent data monitoring committee.
The results of the analysis demonstrated that use of Imfinzi, combined with standard-of-care etoposide and platinum-based chemotherapy in the first-line setting, led to a “statistically significant and clinically meaningful” improvement in overall survival (OS) compared to chemotherapy alone.
Following this analysis, the trial will now continue to further assess the impact on OS in combination with tremelimumab and chemotherapy.
The condition SCLC is an area with significant unmet need, and patients only have access to a handful of treatment options, making these results all the more impactful for affected patients.
“The Phase 3 CASPIAN results offer new hope for patients who are facing the devastating diagnosis of small cell lung cancer, and for whom new medicines are urgently needed,” commented José Baselga, Executive Vice President, Oncology R&D at AstraZeneca. “This is the first trial offering the flexibility of combining immunotherapy with different platinum-based regimens in small cell lung cancer, expanding treatment options.”
The company also announced that it will present these findings in full at an upcoming medical meeting.
Matt Fellows
Related Content
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …
